The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.
 
Dirk Schadendorf
Honoraria - Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Incyte; Merck; Novartis; Roche
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; Pierre Fabre; Roche/Genentech
 
Jean Jacques Grob
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Paul D. Nathan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis; Pierre Fabre
 
Michael A. Davies
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi; Vaccinex
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst)
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo; Strata Oncology; X4 Pharma
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Asana Biosciences; Bristol-Myers Squibb; Genentech; Incyte; Lilly; Loxo; Merck; Novartis; Oncoceutics; Roche; Sanofi; Shattuck Labs; Tolero Pharmaceuticals
Research Funding - Novartis; Sanofi
 
Matthew Squires
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Savina Jaeger
Employment - Novartis
 
William Powell
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Research Funding - Leica Biosystems
 
Puay Tan
Employment - Novartis
 
Caroline Robert
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Novartis; Roche